Interview
Emily Kramer Golinkoff | LeadersLink
- Breakthrough treatments are expected to benefit approximately 90% of the cystic fibrosis (CF) population, though individuals with two copies of a rare nonsense mutation will not receive benefit from these specific advances.
- The organization's primary mission is to rapidly develop life-saving treatments specifically for the remaining 10% of patients affected by nonsense mutations.
- A spun-out CF gene therapy company is currently in the process of submitting a new drug application to the FDA.
- A patient registry and clinical trial matchmaking program have been launched to connect eligible patients with relevant trials and expedite recruitment efforts.
- All initiatives are directed toward accelerating research and drug development for patients with nonsense mutations of cystic fibrosis.
- Two strategic goals established at the inception of LeadersLink involved implementing policies for intellectual property, monetization, and academic grant returns, alongside developing a process for vetting internal investment opportunities.
- Significant progress has been achieved on both policy adoption and investment vetting, resulting in the development of a revenue-sharing model for academic grants.
- The first round of grant awards under the new policy was completed during January and February of the current year.
- The criteria developed for vetting anti-infective opportunities are designed to be applicable to other therapeutic areas beyond their initial scope.
- Dr. Chandra Gose joined as chief scientific officer in January after a search that spanned over one year, tasked with overseeing all research, drug development, and strategic investments.
- The chief scientific officer is finalizing a scientific roadmap to outline priority therapeutic areas and recommend financing allocations between grants and strategic investments.
- Grant contract negotiations experienced delays exceeding initial expectations, prompting the organization to secure additional legal resources to accelerate the process.
- Access to the Faster Cares network is anticipated to provide immense value in supporting the organization's efforts.
- All actions undertaken are intended to increase the overall impact of the organization, referred to as "Emily's entourage."